|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.70 USD | -5.68% |
|
-5.23% | +40.00% |
| Dec. 08 | Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia |  |
| Dec. 08 | Why the Fed's Next Move Matters More Than Markets Admit | |
| Capitalization | 18.98B 16.34B 15.34B 14.26B 26.29B 1,711B 28.68B 179B 69.22B 808B 71.25B 69.73B 2,961B | P/E ratio 2025 * |
15.6x | P/E ratio 2026 * | 14.4x |
|---|---|---|---|---|---|
| Enterprise value | 14.99B 12.9B 12.11B 11.26B 20.76B 1,351B 22.65B 141B 54.66B 638B 56.26B 55.06B 2,338B | EV / Sales 2025 * |
3.01x | EV / Sales 2026 * | 2.44x |
| Free-Float |
97.51% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Incyte Corporation
| 1 day | -5.68% | ||
| 1 week | -5.23% | ||
| Current month | -7.43% | ||
| 1 month | -8.76% | ||
| 3 months | +11.71% | ||
| 6 months | +40.61% | ||
| Current year | +40.00% |
| 1 week | 94.34 |  | 103.68 |
| 1 month | 94.34 | | 109.28 |
| Current year | 53.56 | | 109.28 |
| 1 year | 53.56 | | 109.28 |
| 3 years | 50.27 | | 109.28 |
| 5 years | 50.27 | | 109.28 |
| 10 years | 50.27 | | 153.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Meury
CEO | Chief Executive Officer | 57 | 2025-06-25 |
Pablo Cagnoni
PSD | President | 61 | 2023-06-04 |
Thomas Tray
DFI | Director of Finance/CFO | 48 | 2025-09-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Julian Baker
CHM | Chairman | 58 | 2025-06-25 |
Herve Hoppenot
CHM | Chairman | 65 | 2015-05-21 |
| Director/Board Member | 71 | 2015-01-19 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.55% | 303 M€ | -21.86% | - |
| 2.94% | 1 M€ | 0.00% | - |
| 2.88% | 1 M€ | +23.34% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.68% | -5.23% | +27.37% | +14.97% | 20.13B | |
| -2.10% | -6.25% | -9.61% | -8.12% | 73.7B | |
| -1.27% | -0.14% | -34.88% | -38.62% | 58.94B | |
| +0.28% | +3.59% | +33.94% | +242.06% | 54.7B | |
| -0.73% | +62.90% | +62.90% | +62.90% | 51.57B | |
| -0.47% | +1.50% | +14.36% | -37.59% | 26.6B | |
| -1.99% | -10.60% | +114.58% | +160.16% | 20.25B | |
| +0.33% | -15.50% | +49.67% | +1,035.07% | 16.58B | |
| +0.81% | +3.43% | +157.87% | +678.20% | 14.19B | |
| -0.04% | -.--% | +55.97% | +154.53% | 14.02B | |
| Average | -1.08% | -2.00% | +47.22% | +226.35% | 35.07B | |
| Weighted average by Cap. | -1.14% | -1.92% | +26.92% | +128.62% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.98B 4.28B 4.02B 3.74B 6.89B 449B 7.52B 46.85B 18.14B 212B 18.67B 18.27B 776B | 5.52B 4.75B 4.46B 4.14B 7.64B 497B 8.33B 51.94B 20.11B 235B 20.7B 20.26B 860B |
| Net income | 1.25B 1.07B 1.01B 936M 1.73B 112B 1.88B 11.74B 4.55B 53.06B 4.68B 4.58B 194B | 1.34B 1.16B 1.09B 1.01B 1.86B 121B 2.03B 12.66B 4.9B 57.24B 5.05B 4.94B 210B |
| Net Debt | -3.99B -3.44B -3.23B -3B -5.53B -360B -6.03B -37.61B -14.56B -170B -14.99B -14.67B -623B | -5.54B -4.77B -4.48B -4.16B -7.67B -500B -8.37B -52.19B -20.21B -236B -20.8B -20.36B -864B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-08 | 96.70 $ | -5.68% | 3,867,945 |
| 25-12-05 | 102.52 $ | +2.05% | 2,357,052 |
| 25-12-04 | 100.46 $ | -1.02% | 2,088,653 |
| 25-12-03 | 101.50 $ | +0.06% | 1,874,701 |
| 25-12-02 | 101.44 $ | -0.59% | 2,438,855 |
Delayed Quote Nasdaq, December 08, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- INCY Stock
Select your edition
All financial news and data tailored to specific country editions
